FutureMeds Appoints Dr Torsten Sernau as Vice President of Medical Operations
FutureMeds is proud to announce a significant expansion of its Executive Leadership Team with the appointment of Dr Torsten Sernau as Vice President of Medical Operations. Dr Sernau joins the company with a wealth of experience spanning 28 years in the clinical research industry, signalling a new chapter in our pursuit of excellence in the dedicated research site model.
As FutureMeds Vice President of Medical Operations, Dr Torsten Sernau will be responsible for nurturing relations with key Pharmaceutical clients, strategising our offerings across all therapeutic areas and enhancing the visibility of FutureMeds in the industry.
“Torsten’s leadership is expected to significantly contribute towards meeting the challenges of our growth trajectory and accelerating patient access to new treatments. His dedication is evident as he plans to visit our sites and countries to gain a firsthand understanding of our medical operations.”
- Radoslaw Janiak, CEO at FutureMeds
With a successful track record spanning 28 years in the clinical research industry, Torsten brings a wealth of expertise and experience that is not only poised to bolster our medical operations significantly but also help FutureMeds address the internal complexities that come with the fast growth of our site network.
"The dedicated site research model has been a passion of mine since I joined the industry. It offers patients access to innovative treatments at scale and provides sponsors with a solution to overcome trial productivity issues commonly seen in traditional study settings. With the great team at FutureMeds, we are committed to enhancing trial productivity and the quality of research for our clients."
- Dr Torsten Sernau, Vice President of Medical Operations
Dr. Sernau earned his medical degree from the University of Saarbrücken in 1993. His early career saw him serving as a physician at the University Hospital in Heidelberg, specialising in Endocrinology and Cardiology until 1995.
In 1995, he started his career in clinical research at Boehringer Mannheim as a Clinical Research Physician and Project Leader in Clinical Drug Development. After gaining three years of experience and delivering clinical trials, he moved to Roche as an International Medical Manager in Global Product Marketing. Two years later, Roche promoted him to Manager of Integrated Health Care Solutions.
In 2001, Dr. Sernau embarked on a notable tenure at PPD, where he held various leadership positions, including Executive Director of Clinical Management, Executive Director of Commercial Strategies and Executive Director of Accelerated Enrollment Solutions.
He was appointed as the Vice President of Commercial Strategies at AES in 2019, where he oversees the development of account-specific strategies for integrated site network and patient access solutions. In 2021, he assumed the role of Vice President of Medical Strategies, where he is responsible for driving medical excellence and developing therapeutic strategy in support of pipeline growth.
Reflecting on his transition, Torsten shared on LinkedIn, “After 22 years with PPD, I am excited to embark on a new journey as VP of Medical Operations at FutureMeds, Europe's fastest-growing network of Dedicated Research Centers. Now, I am thrilled to join FutureMeds' executive leadership team on their mission of transforming trial efficiency and patient experience across Europe whilst building the best dedicated clinical research network on the continent.”
FutureMeds is the 1st European Independent Dedicated DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 18 countries.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.